3/12
07:30 am
sgmt
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
Low
Report
Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates
3/11
01:27 pm
sgmt
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Low
Report
Sagimet Biosciences Inc. (NASDAQ: SGMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
3/11
08:00 am
sgmt
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
Medium
Report
Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
3/7
04:30 pm
sgmt
https://seekingalpha.com/article/4765804-sagimet-biosciences-denifanstat-should-be-worth-more-today [Seeking Alpha]
Low
Report
https://seekingalpha.com/article/4765804-sagimet-biosciences-denifanstat-should-be-worth-more-today [Seeking Alpha]
2/19
08:00 am
sgmt
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
Low
Report
Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium
1/6
08:00 am
sgmt
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference
High
Report
Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference